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Individualized estimation of prognosis after cardiac resynchronization therapy (CRT) remains
challenging. Our aim was to develop a multiparametric prognostic risk score (CRT-
SCORE) that could be used for patient-specific clinical shared decision making about CRT
implantation. The CRT-SCORE was derived from an ongoing CRT registry, including 1,053
consecutive patients (age 67 ± 10 years, 76% male). Using preimplantation variables, 100
multiple imputed datasets were generated for model calibration. Based on multivariate Cox
regression models, cross-validated linear prognostic scores were calculated, as well as sur-
vival fractions at 1 and 5 years. Specifically, the CRT-SCORE was calculated using
atrioventricular junction ablation, age, gender, etiology, New York Heart Association class,
diabetes, hemoglobin level, renal function, left bundle branch block, QRS duration, atrial
fibrillation, left ventricular systolic and diastolic functions, and mitral regurgitation, and
showed a good discriminative ability (areas under the curve 0.773 at 1 year and 0.748 at 5
years). During the long-term follow-up (median 60 months, interquartile range 31 to 85),
all-cause mortality was observed in 494 (47%) patients. Based on the distribution of the
CRT-SCORE, lower- and higher-risk patient groups were identified. Estimated mean sur-
vival rates of 98% at 1 year and 92% at 5 years were observed in the lowest 5% risk group
(L5 CRT-SCORE: −4.42 to −1.60), whereas the highest 5% risk group (H5 CRT-SCORE:
1.44 to 2.89) showed poor survival rates: 78% at 1 year and 22% at 5 years. In conclu-
sion, the CRT-SCORE allows accurate prediction of 1- and 5-year survival rates after CRT
using readily available and CRT-specific clinical, electrocardiographic, and echocardiographic
parameters. The model may assist clinicians in counseling patients and in decision
making. © 2017 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am
J Cardiol 2017;120:2008–2016)
Despite the knowledge that beneficial effect of cardiac
resynchronization therapy (CRT) is influenced by multiple
factors, a comprehensive and customized approach to esti-
mate prognosis after CRT is lacking, although it would be
of crucial importance in clinical decision making for high-
risk patients with heart failure and for this relatively invasive
and costly procedure. Ideally, short-term and long-term sur-
vival rates should be accurately estimated and with a patient-
specific approach to appropriately tailor CRT implantation.
Our objective was therefore to develop an individualized CRT
multiparametric prognostic risk score using readily avail-
able heart failure and CRT-specific variables in a large registry
of unselected patients who underwent CRT. This score may
facilitate shared decision making between patients with heart
failure and their physicians.
Methods
All patients consecutively included in the ongoing
CRT registry from the Department of Cardiology of the
Leiden University Medical Centre (Leiden, The Nether-
lands) from August 1999 to July 2013 were considered for
this analysis.1 Among these patients, only those who under-
went CRT device implantation according to the presence of
a left ventricular ejection fraction (LVEF) of ≤35%, a QRS
duration of ≥120 ms, and a New York Heart Association
(NYHA) functional class II-ambulatory IV, despite optimal
heart failure medical treatment, were included.2 Further-
more, patients with a decompensated heart failure before
the implantation or a recent myocardial infarction (<3
months) were excluded. All patients underwent extensive
clinical evaluation and transthoracic 2-dimensional
echocardiography before the CRT implantation. All patients
were scheduled for regular visits at the outpatient clinic of
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our center and/or at the referral hospital on the long-term
follow-up. Patient data were prospectively collected in the
departmental Cardiology Information System (EPD-Vision;
Leiden University Medical Center, Leiden, The Nether-
lands) and were subsequently analyzed. The Dutch Central
Committee on Human-related Research (CCMO) allows
the use of anonymous data without previous approval from
an institutional review board, provided that the data are
acquired for routine patient care. All data used for this
study were acquired for clinical purposes and were handled
anonymously.
Before CRT implantation, extensive clinical evaluation
was performed and included NYHA functional class, quality-
of-life score according to the Minnesota Living with Heart
Failure Questionnaire (higher scores indicate poorer quality
of life), blood pressure, and exercise capacity by the 6-minute
walk test.3,4 Hemoglobin levels and serum creatinine were
also routinely assessed before implantation. Assessment of
renal function evaluation was based on the glomerular fil-
tration rate (GFR) estimation in milliliter per minute.5 The
etiology of heart failure was considered ischemic in the
presence of a significant coronary artery disease (>50%
stenosis in ≥1 major epicardial coronary artery) on coro-
nary angiography and/or a history of myocardial infarction
or revascularization. The number of patients with atrial fi-
brillation (AF) at baseline, either chronic or paroxysmal,
was noted. The atrioventricular junction (AVJ) ablation for
AF before CRT implantation was recorded. The presence of
left bundle branch block (LBBB) on a 12-lead electrocar-
diogram was defined by the presence of a QRS duration of
≥120 ms with typical features of LBBB described by the
current guidelines.6
Echocardiographic studies were performed with patients
in the left lateral decubitus position using a commercially
available ultrasound system (Vivid 7 and e9; General Elec-
tric Vingmed Ultrasound, Horten, Norway) equipped with
3.5 MHz and M5S transducers. Images were digitally stored
for offline analysis in cine-loop format (EchoPac 112.0.1;
GE-Vingmed, Horten, Norway). Left ventricular (LV) end-
diastolic volume and end-systolic volume and LVEF were
calculated using the Simpson biplane rule.7 Mitral regurgi-
tation severity was evaluated using a semiquantitative
multiparametric approach from color Doppler and Doppler
acquisitions and was graded according to the recommenda-
tions of the European Association of Cardiovascular Imaging
as mild (grade 1), moderate (grade 2), and severe (grades 3
to 4).8 LV diastolic function was evaluated according to
current recommendations using the multiparametric ap-
proach, including transmitral flow Doppler velocities and
tissue Doppler imaging-derived mitral annular velocities.9
LV diastolic dysfunction was therefore graded (grades 1, 2,
and 3) and restrictive function was considered in case of an
LV diastolic dysfunction grade 3.9
Survival data were obtained by a review of medical records
and by a retrieval of survival status through the municipal civil
registries. The end point was all-cause mortality. Cardiovas-
cular death was defined as death due to progression of heart
failure, sudden cardiac death, myocardial infarction, ven-
tricular arrhythmias, other cardiac cause, and stroke according
to a modified Hinkle-Thaler system.10 Furthermore, patients
who underwent heart transplantation or LV assist device im-
plantation were classified as cardiac death on the day of their
procedure.
Variables were presented as mean values ± standard de-
viation, median and interquartile range, or frequencies and
percentages in the case of categorical variables. To account
for missing observations, 100 multiple imputed datasets were
generated (using the package MICE, R; TNO, Leiden, the
Netherlands), based on the following variables: age, gender,
etiology, AF, QRS duration, LBBB, NYHA functional class,
diabetes mellitus, GFR, hemoglobin level, mitral regurgita-
tion, LVEF, and LV diastolic dysfunction, as well as the
survival time and censoring indicator.11 For each multiple
imputed dataset, the predictive performance of estimated sur-
vival outcomes using Cox regression was estimated from a
10-fold cross-validatory approach.12 Estimation was carried
out on a fixed set of clinical predictors, which were chosen
as well-known prognostic parameters of long-term outcome
after CRT based on the relevant published CRT literature.1,2,13,14
Considering the multiple imputation, an additional or unnec-
essary statistical complexity was therefore prevented using
predefined parameters at the univariate and multivariate Cox
regression analyses.12 The estimation of each individual Cox
regression model was carried out as follows. First, a Cox model
was generated, which adjusts for age, gender, and AVJ ab-
lation. The linear predictor derived in this model was entered
as an offset in a new Cox regression model with the
abovementioned prognostic relevant variables. For each left-
out partition of the data within the cross-validatory procedure
and for each multiple imputation, the resulting model was then
applied to the left-out data and their cross-validated linear prog-
nostic scores were calculated, as well as the cross-validated
(per-patient) survival fractions at 1 and 5 years. For each mul-
tiple imputed dataset, the (cross-validated) receiver operating
characteristic (ROC) curve was calculated to examine the dis-
criminatory value of the joint set of variables for the prediction
of the survival end point. The area under the curve (AUC)
calculation was adjusted for censoring (package timeROC,
R; University of Copenhagen, Copenhagen, Denmark) and
based on the cross-validated prognostic scores at 1 and 5
years.15 The CRT-SCORE was simplified by reducing the
number of parameters required for the calculation of the score
by rounding without loss of discriminatory capacity. To cal-
culate the CRT-SCORE on a new patient, each variable in
the multivariate model was multiplied by its pooled rounded
regression coefficient and the products were summed. For clini-
cal decision making, life tables were generated using averaged
cross-validated prognostic scores across all imputations into
a single combined mean score. Likewise, the cross-validated
per-patient survival fractions at 1 and 5 years were aver-
aged across all imputations to generate a single mean
consensus survival fraction. Evaluation of the 1-year sur-
vival rate was performed considering the currently
recommended life expectancy of 1 year for CRT implantation.2
Analysis of the 5-year survival rate was performed to give
an estimation of the long-term outcome in this high-risk patient
population. Using these aggregated multiple imputation cross-
validation results, the 0%, 5%, 10%, 20%, 40%, 60%, 80%,
90%, 95%, and 100% percentiles of the cross-validated prog-
nostic score range were identified. To improve the readability,
the groups based on the prognostic score were renamed based
on the corresponding range, that is, the highest 5% score (the
2009Heart Failure/CRT Survival Score
range 95% to 100%) was named as H5. The range 40% to
60% was named M, and the lowest percentage, that is, the
range 0% to 5%, was named L5. The groups were named H5,
H10, H20, H40, M, L40, L20, L10, and L5, respectively. For
each interval between subsequent percentiles of the cross-
validated predictor, the 0%, 25%, 50%, 75%, and 100%
percentiles of 1- and 5-year survival fractions were calcu-
lated within that corresponding prognostic range as well as
the corresponding Kaplan-Meier estimates (for 1 and 5 years).
Kaplan-Meier estimates were also generated for the 0 to 20,
20 to 40, 40 to 60, 60 to 80, and 80 to 100 percentile ranges
of the average cross-validated prognostic score. The sepa-
rate Cox model estimates were pooled across the 100 multiple
imputed datasets, and standard errors and p values were ad-
justed for multiple imputations (package MICE, R) using the
Rubin rules.11,16 The calculated univariate and multivariate Cox
regression tests were 2-sided and a p value of <0.05 was con-
sidered statistically significant. Windows IBM SPSS Statistics
software (SPSS version 20.0; IBM SPSS statistics, Chicago,
Illinois) and R version 3.0.1 (R Development Core Team,
Vienna, Austria) were used for data analyses.
Results
A total of 1,053 CRT patients were included in the analy-
sis. The clinical characteristics are listed in Table 1. During
the long-term follow-up (median 60 [interquartile range 31
to 84] months), all-cause mortality was observed in 494
(47%) patients, 438 (87%) of which were considered as
cardiovascular death. The datasets were nearly complete
(>99%) with the exception of LV diastolic function. This
variable was missing in 49.8% of the patients. The missing
datasets were imputed using 100 multiple imputation and
repeated after 10-fold cross-validatory approach for each
imputed dataset. The univariate Cox regression analysis is
listed in Table 2. The predefined and the additional param-
eters that were significant at the univariate analysis were
entered in a multivariate model; besides age, gender, and
AVJ ablation (predefined for adjustment), only ischemic
etiology, diabetes, QRS duration of ≥150 ms, NYHA func-
tional class, renal function, LVEF, mitral regurgitation grade
≥3, and restrictive LV diastolic function were indepen-
dently associated with mortality after CRT implantation after
rounding (Table 3). Furthermore, the LBBB, AF, and the




Age, (years) 67 ± 10
Men, n (%) 805(76)
New York Heart Association functional class II 250(24%)
New York Heart Association functional class III 713(68%)
New York Heart Association functional class IV 90(9%)
Six-minute walk distance, (meters) 306 ± 125
Minnesota quality of life score, (point) 35 ± 19
Systolic blood pressure, (mmHg) 124 ± 21
Diastolic blood pressure, (mmHg) 73 ± 12
Glomerular filtration rate, (ml/min) 70 ± 32




Atrio-ventricular junction ablation 42(4%)
QRS duration, (ms) 166 ± 26




Angiotensin II receptor blocker
928(88%)
Amiodarone, 204(19%)
Left ventricular end-diastolic volume, (ml) 218 ± 80
Left ventricular end-systolic volume, (ml) 165 ± 71
Left ventricular ejection fraction, (%) 26 ± 8
Mitral regurgitation grade ≥3 182(18%)
Restrictive left ventricular diastolic function 175(33%)
Table 2
Univariate Cox-regression analysis for all-cause mortality after cardiac
resynchronization therapy
Variable β SE p-Value
Age, (per year) 0.038 0.005 <0.001
Men 0.397 0.116 0.001
Atrio-ventricular junction ablation -0.069 0.234 0.768
New York Heart Association functional class III 0.653 0.133 <0.001
New York Heart Association functional class IV 1.293 0.179 <0.001
Glomerular filtration rate, per ml/min −0.023 0.002 <0.001
Hemoglobin, (per mmol/L) −0.279 0.047 <0.001
Ischemic etiology 0.579 0.095 <0.001
Diabetes mellitus 0.522 0.103 <0.001
Left bundle branch block −0.315 0.093 0.001
QRS duration ≥150 ms −0.170 0.098 0.084
Atrial fibrillation 0.413 0.106 <0.001
Left ventricular ejection fraction, (per %) −0.028 0.006 <0.001
Mitral regurgitation grade ≥3 0.507 0.105 <0.001
Restrictive left ventricular diastolic dysfunction 0.432 0.124 0.001
Table 3
Refitted multivariate Cox-regression for all-cause mortality after cardiac
resynchronization therapy after rounding (simplified CRT-SCORE)
Variable HR Β SE p-Value
Age, (per year) 1.038 0.037 0.005 <0.001
Men 1.443 0.367 0.116 0.001
Atrio-ventricular junction ablation 0.845 −0.169 0.234 0.469
New York Heart Association
functional class III
1.483 0.394 0.137 0.004
New York Heart Association
functional class IV
2.284 0.826 0.189 <0.001
Glomerular filtration rate,
per ml/min
0.987 −0.013 0.002 <0.001
Hemoglobin, (per mmol/L) 0.919 −0.084 0.049 0.084
Ischemic etiology 1.247 0.221 0.099 0.026
Diabetes mellitus 1.675 0.516 0.107 <0.001
Left bundle branch block 0.841 −0.173 0.096 0.072
QRS duration ≥150 ms 0.856 −0.156 0.103 0.130
Atrial fibrillation 1.049 0.048 0.122 0.691
Left ventricular ejection fraction,
(per %)
0.974 −0.026 0.006 <0.001
Mitral regurgitation grade ≥3 1.296 0.259 0.109 0.018
Restrictive left ventricular
diastolic dysfunction
1.384 0.325 0.137 0.018
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the CRT-SCORE, considering that their clinical value and/
or a p value <0.1. ROC curves at 1- and 5-year survival
rates based on the 10-fold cross-validation within each mul-
tiple imputation were generated (supplemental file,
Supplementary Figures S1 and S2). The discriminative ability
of the model was good with an area under the ROC curve
of 0.773 (minimum 0.733 and maximum 0.753) at 1 year
and 0.748 (minimum 0.728 and maximum 0.734) at 5 years.
Predicting a patient’s risk in daily clinical practice re-
quires adding up the β-coefficients of the predictors from
Table 3 to calculate the mortality risk score. The CRT-
SCORE was therefore calculated as follows:
CRT-SCORE = − × + ×
+ ×
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Kaplan-Meier curves were generated per 20% of the study
population during the entire follow-up (Figure 1). The CRT
score was used as a risk score to estimate individual sur-
vival rates. Using Cox regression analysis, the survival curves
were generated for 1- and 5-year survival rates stratified per
20% prognostic index (Figure 2). For clinical decision making,
the individual risk scores were displayed in more detail, per
5% of the prognostic index in the high and low ends of the
CRT score ranging from L5 to H5 (Table 4A and B). In the
lowest-risk group (L5; CRT score −4.42 to −1.60), the esti-
mated mean survival rate was 98% at 1 year and 92% at 5
years. More interestingly, in the highest-risk group (H5; CRT
score 1.44 to 2.89), the survival rate was 78% at 1 year and
22% at 5 years (Table 4A and B). The groups between the 2
ends with their corresponding CRT-SCORE are listed in
Table 4A for the 1-year survival fractions and in Table 4B
for the 5-year survival fractions. Also, a graphical presenta-
tion of these data is shown for the 1-year survival fractions
and for the 5-year survival fractions in Figure 3. Although
the CRT-SCORE was estimated for all-cause mortality, the
cause-specific incidence of mortality was evaluated among
the CRT-SCORE percentiles. As shown in Figure 4, the in-
crease in risk groups was associated with more likelihood of
cardiovascular mortality, suggesting therefore that the CRT-
SCORE is able to risk-stratify also cardiovascular mortality.
Discussion
Using preimplantation clinical, electrocardiographic, and
echocardiographic data from a large cohort of unselected pa-
tients treated with CRT, we derived a risk stratification score
(CRT-SCORE), which was able to predict mortality at 1 and
5 years after implantation. Importantly, the CRT-SCORE iden-
tified the highest-risk group (H5) characterized by a very poor
Figure 1. Kaplan-Meier curve of the overall survival rate after CRT implantation. The survival rate indexed per 20% of the CRT-SCORE, that is, the top
20% (H20 and higher) in black and the bottom 20% (L20 and lower) in light blue. (Color version available online.)
2011Heart Failure/CRT Survival Score
prognosis both at the short- and long-term follow-ups,
suggesting the very limited beneficial effect of CRT in these
patients. For a potential implementation in clinical practice
and widespread use, the CRT-SCORE calculator is possible
for smartphone applications and/or online using the CRT-
SCORE website (see Appendix).
In addition to the criteria currently recommended by the
guidelines, which include the NYHA class, the LVEF, the
QRS morphology, and the duration, several clinical, electro-
cardiographic, and echocardiographic parameters have been
suggested to further modulate the spectrum of CRT re-
sponse and, more importantly, to predict prognosis after
Figure 2. (A) Cross-validated survival estimation per 20% prognostic index at 1 year after CRT implantation. (B) Cross-validated survival estimation per 20%
prognostic index at 5 years after CRT implantation.
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implantation.1,2,13,14,17–20 In the present study, most of these
preimplantation parameters confirmed their significant asso-
ciation with survival rate through the univariate and multivariate
Cox regression analyses or were a priori included in the
CRT-SCORE: gender, NYHA class, etiology of heart failure,
diabetes, renal function, hemoglobin level, AF, LBBB mor-
phology, severely prolonged QRS duration, severe mitral
regurgitation, and restrictive LV diastolic function. Estima-
tion of short- and long-term prognoses in patients with
heart failure is a challenge for clinicians and can be either
over- or underestimated. Considering the costs and the po-
tential complications of the procedure, a life expectancy of
at least 1 year is currently advised when referring patients
for CRT, although no specific criteria for this assessment
are suggested.2 Development of a patient-specific and CRT-
specific multiparametric prognostic risk score would be
therefore of great clinical value in decision making. Involve-
ment of patients in this process, the so-called shared decision
making, would also require a reliable estimation of the
long-term beneficial effect of CRT using readily available
and easily understandable parameters. With this aim, several
studies already proposed different prognostic models.21–24
The Seattle Heart Failure Model is an accepted prognostic
score of 25 parameters for predicting the survival rate in
patients with heart failure, although it has been shown to
systematically underestimate mortality risk, particularly in
patients with implanted devices.22 CRT studies using the
Seattle Heart Failure Model show a relatively high survival
rate for the highest-risk category of patients compared with
the cumulative incidence (91% vs 93% at 1 year and 66%
vs 75% at 5 years), suggesting a suboptimal prognostic
performance at the short-term follow-up,23 and the rela-
tively low discriminative ability (AUC = 0.64) at the long-
term follow-up.22 Other CRT risk stratification scores
incorporating baseline clinical parameters such as the pres-
ence of advanced chronic kidney disease, age, NYHA class,
LVEF impairment, and AF included patients with a narrow
QRS complex, in whom CRT implantation is currently
discouraged,2 and surprisingly showed that patients with
higher-risk scores and less CRT benefit had a wider QRS
duration.24 The most comprehensive CRT prediction score,
so far, was proposed by Gasparini et al, who included pa-
tients from multiple European centers.21 Gasparini et al’s
study showed an acceptable discriminatory capacity of a
model comprising 8 clinical and echocardiographic param-
eters (AUC = 0.70). However, in 89% of the validation
population, an LBBB morphology was present, and more-
over, essential prognostic parameters such as renal function
and mitral regurgitation were not included in their final
model. Furthermore, missing data were at random and not
completely at random, which could have introduced bias25,26
and probably explain the discrepancy between the predicted
and the observed survival rates at the 6-year follow-up (better
for the predicted survival rate in the lowest-risk group). The
CRT-SCORE was shown to have a higher discriminative
value (by a higher AUC) than other risk stratification models
and was used to identify different patient risk groups. As
clearly shown by the distribution in Figure 1, patients in the
Table 4A
Quantiles of cross-validated survival fractions free from all-cause mortality (columns) versus range of cross-validated linear predictor (rows) at 1 year
Cross-validated survival fractions at 1 year
Group name Proportion of patients CRT-SCORE 0% 25% 50% 75% 100%
L5 0–5% [−4.42–−1.60] 0.99 0.99 0.99 0.99 1.00
L10 5–10% [−1.60–−1.31] 0.98 0.99 0.99 0.99 0.99
L20 10–20% [−1.31–−0.82] 0.97 0.98 0.98 0.98 0.98
L40 20–40% [−0.82–−0.16] 0.95 0.96 0.96 0.97 0.97
M 40–60% [−0.16–0.28] 0.93 0.93 0.94 0.95 0.95
H40 60–80% [0.28–0.79] 0.88 0.89 0.91 0.92 0.93
H20 80–90% [0.79–1.18] 0.83 0.84 0.86 0.87 0.88
H10 90–95% [1.18–1.44] 0.78 0.80 0.81 0.82 0.83
H5 95–100% [1.44–2.89] 0.36 0.68 0.73 0.76 0.78
Table 4B
Quantiles of cross-validated survival fractions (columns) free from all-cause mortality versus range of cross-validated linear predictor (rows) at 5 years
Cross-validated survival fractions at 5 years
Group name Proportion of patients CRT-SCORE 0% 25% 50% 75% 100%
L5 0–5% [−4.42–−1.60] 0.93 0.94 0.95 0.96 0.99
L10 5–10% [−1.60–−1.31] 0.91 0.92 0.92 0.93 0.93
L20 10–20% [−1.31–−0.82] 0.86 0.87 0.89 0.90 0.91
L40 20–40% [−0.82–−0.16] 0.75 0.78 0.80 0.83 0.86
M 40–60% [−0.16–0.28] 0.64 0.68 0.70 0.73 0.75
H40 60–80% [0.28–0.79] 0.48 0.53 0.57 0.61 0.64
H20 80–90% [0.79–1.18] 0.34 0.38 0.41 0.45 0.48
H10 90–95% [1.18–1.44] 0.25 0.28 0.31 0.33 0.34
H5 95–100% [1.44–2.89] 0.00 0.11 0.17 0.21 0.25
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highest 5% (H5) risk group demonstrated a remarkable de-
crease in the survival rate at 1 year (36% to 78% survival
rates), suggesting that a more weighted and tailored deci-
sion should be taken in these patients when referring for
CRT because, in most of these patients, life expectancy is
under the time range currently suggested (1 year). On the
other hand, identification of low-risk patients might be rel-
evant to determine follow-up checkups and for a potential
early discharge from the outpatient clinic of tertiary hospi-
tals. Compared with previously proposed scores, the present
Figure 3. (A) Cross-validated survival fractions at 1 year in 9 CRT-SCORE segments ranging from the highest 5% (H5) to the lowest 5% (L5). (B) Cross-
validated survival fractions at 5 years in 9 CRT-SCORE risk groups ranging from the highest 5% (H5) to the lowest 5% (L5).
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study also used an appropriate approach for missing data.
Although no estimation method is fail-safe, the multiple
imputation method is considered the optimal approach re-
garding missing values. Several limitations should also be
mentioned. Several parameters were not included in the
model: (1) medical therapy considering the already opti-
mized pharmacologic treatment in all patients; (2) biochemical
data (e.g., N-terminal probrain natriuretic peptide) were not
systemically available; (3) echocardiographic measure-
ments of LV mechanical dyssynchrony due to vendor
dependency and variability27; and (4) CRT response, consid-
ered a postimplantation assessment. Furthermore, CRT devices
without defibrillator backup were not evaluated separately,
considering the small number (61 patients, 5.8%) and because
the CRT-SCORE was based on the overall mortality (the
specific cause of death would not affect the score). Finally,
both external validation and comparison with previous risk
stratifications scores could not be performed. We have per-
formed an internal validation and encourage future studies
to perform further validation of our findings and compari-
son of the CRT-SCORE with previous scores in larger cohorts.
In conclusion, the CRT-SCORE allows prediction of the
survival rate in CRT using readily available and CRT-
specific clinical, electrocardiographic, and echocardiographic
characteristics. The model provides estimates of 1- and 5-year
mortalities that may assist clinicians in counseling patients
and families and guide clinical shared decision making.
Furthermore, by estimation of the prognosis, the CRT-
SCORE may facilitate an optimized and tailored outpatient
follow-up.
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